A transformative clinical trial offers three critical insights for patients and clinicians managing intermediate-risk breast cancer. First, genetic testing through the Oncotype DX assay can identify approximately 6,600 UK patients annually who can safely avoid chemotherapy, sparing them from significant treatment toxicity. Second, this precision medicine approach maintains over 93% five-year survival rates regardless of chemotherapy use in appropriately selected populations.
Third, age matters: while postmenopausal women show no survival benefit from added chemotherapy, premenopausal women demonstrate modest but meaningful improvements with combination treatment. These practical findings mean that breast cancer patients should discuss genetic testing with their oncologists before committing to chemotherapy protocols.
The RxPONDER trial demonstrates that informed, data-driven treatment decisions—guided by individual genetic profiles—can reduce unnecessary suffering while preserving survival outcomes. For patients facing intermediate-risk diagnoses, genetic testing represents an opportunity to personalize care and potentially avoid debilitating side effects.
Read the full article on GMJ Newsroom.
Was this article helpful?
